Keywords: Sanofi, :ixissenatide, Type 2 diabetes, USA, FDA, Zealand Pharma

US FDA accepts Sanofi's NDA for diabetes drug lixisenatide

Article | 19 February 2013

Print This

The US Food and Drug Administration has accepted for review French drug major Sanofi’s (Euronext: SAN) New Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in